ON DEMAND WEBINAR
Duration: 1 hour

Nine out of 10 clinical trials for new drugs fail. The numbers are even more sobering for cancer-therapy trials: Oncology drugs have just a 3.4 percent probability of succeeding. For more than a decade, their success rates have trailed even trials for autoimmune diseases and vaccines.

Still, cancer drugs can and are commercialized. From 2003 to 2020, 124 oncology therapies were approved by the U.S. Food and Drug Administration. What makes this possible is knowing the key factors to consider when making go and no-go decisions at each juncture of development, so you can build the right roadmap for your product. In this webinar, you will learn how examining each step of drug development helps sponsors find success for cancer therapies. Topics include:

• How to fill gaps and avoid common pitfalls of oncology drug development
• The importance of early-phase planning, from optimum dosage to formulation
• The role of EOP (end-of-phase) planning, such as regulatory feedback

SPEAKERS

Marc Pipas
Senior Medical Director
Rho

Kevin Barber
Senior Vice President
Regulatory Strategy & Submissions
Rho

Joseph Watson
Director
Regulatory Strategy
Rho